Lynparza

Tesaro Wants a Stronger Grip in Ovarian Cancer
Yahoo/Motley Fool
Tue, 03/27/18 - 10:10 pm
Tesaro
AstraZeneca
Clovis Oncology
ovarian cancer
Zejula
Rubraca
Lynparza
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
Sat, 03/10/18 - 09:17 am
AstraZeneca
Clovis Oncology
PARP inhibitors
Lynparza
ovarian cancer
breast cancer
Rubraca
Zejula
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
Investors Business Daily
Sat, 02/3/18 - 09:09 am
AstraZeneca
Lynparza
Tesaro
cancer
Rubraca
Clovis Oncology
Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma
Endpoints
Sat, 01/20/18 - 02:56 pm
AstraZeneca
Lynparza
Merck
ovarian cancer
asthma
Japan
Fasenra
EA Pharma
elobixibat
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Endpoints
Fri, 01/12/18 - 10:39 am
AstraZeneca
PARP inhibitors
FDA
Lynparza
metastatic breast cancer
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
Fri, 01/5/18 - 10:28 am
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Endpoints
Tue, 01/2/18 - 11:44 am
Bristol-Myers Squibb
AstraZeneca
Opdivo
Lynparza
China
These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
Investors Business Daily
Tue, 01/2/18 - 11:42 am
Europe
AstraZeneca
Lynparza
ovarian cancer
Novo Nordisk
diabetes
semaglutide
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
Endpoints
Fri, 12/8/17 - 11:46 am
Pfizer
AstraZeneca
talazoparib
advanced breast cancer
Lynparza
PARP inhibitors
3 Companies Competing to Gain Lead in Ovarian Cancer Market
Yahoo/Zacks.com
Sat, 11/25/17 - 12:35 pm
ovarian cancer
AstraZeneca
Merck
Lynparza
Rubraca
Clovis Oncology
Zejula
Tesaro
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
Wed, 11/15/17 - 08:51 pm
AstraZeneca
Merck
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Zejula
Rubraca
Lynparza
[forum discussion]What's up in Oncology?
Cafepharma Message Boards
Wed, 10/11/17 - 09:59 am
Merck
oncology
drug reps
Lynparza
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Fierce Pharma
Mon, 10/2/17 - 10:10 pm
AstraZeneca
Tesaro
Clovis Oncology
PARP inhibitors
drug pricing
ovarian cancer
Lynparza
Zejula
Rubraca
Ovarian Cancer Market Still Up For Grabs
Barron's
Sat, 08/19/17 - 10:48 am
ovarian cancer
Lynparza
Tesaro
AstraZeneca
Clovis Oncology
Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza
Endpoints
Thu, 08/17/17 - 11:54 pm
Tesaro
AstraZeneca
Merck
FDA
Lynparza
Zejula
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B
Fierce Pharma
Fri, 07/28/17 - 11:31 am
AstraZeneca
Merck
Lynparza
Imfinzi
AstraZeneca Is Focused on Lynparza’s Label Expansion in 2017
Market Realist
Mon, 07/10/17 - 11:39 am
AstraZenca
Lynparza
BRCA-mutated ovarian cancer
ovarian cancer
New test may turn AZ's Lynparza into precision drug for prostate cancer
Yahoo/Reuters
Mon, 06/19/17 - 07:16 am
AstraZeneca
Lynparza
prostate cancer
ASCO17: AstraZeneca pumps up expectations on near-term cancer drug wins, looking to shed a rep for failure
Endpoints
Tue, 06/6/17 - 09:44 am
AstraZeneca
ASCO 2017
Lynparza
breast cancer
AstraZeneca's Lynparza Slows Breast Cancer Caused By BRCA Mutations By 42%
Forbes
Sun, 06/4/17 - 11:53 am
AstraZeneca
Lynparza
breast cancer
BRCA-mutant breast cancer
ASCO 2017

Pages